European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Folate-Target Nanodevices To Activated Macrophages For Rheumatoid Arthritis

Objetivo

FOLSMART will bring to phase I clinical trials novel folate-based nanodevices (FBN) for the treatment of rheumatoid arthritis (RA). These nanodevices for folic acid (FA)-mediated targeting of activated macrophages showed improved clinical scores in a mouse model of RA when compared to methotrexate (MTX), first-line drug therapy for the treatment of RA. In this way, FBN will be benchmarked against this drug. MTX has significant associated toxicity and second-line biological therapies pose a great economic burden to hospital/public health systems. In parallel, nanodevices encapsulating Sulfasalazine (SSZ), will be tested. SSZ is a second line indication for the treatment of RA, unresponsive to MTX or MTX–intolerant patients. Furthermore, FOLSMART proposes the optimization of mechanisms for the release of the drugs, through pH and temperature-sensitive nanodevices. Exploitation and business plans will be elaborated. In parallel, the initial economic evaluation of all proposed treatments will be performed to validate these claims.

Specific technological objectives of FOLSMART will be:

Good Manufacturing Practice (GMP) production of the FBN based therapies which have been positively bench-marked in the previous FP7 European project NANOFOL in comparison with the use of MTX in a RA mouse model:
-Liposomal MTX and SSZ with FA-“neck domain” peptide as targeting agent
-Nanoparticles from HSA-FA/MTX conjugates and SSZ
-Optimization of mechanisms of drug release and application to other fields

Pre-clinical development on RA models:
-Toxicology and pharmacokinetics, to determine tolerability and efficacy benefit in two animal models rat and dog, under Good Laboratory Practice (GLP) standards
-Genotoxicity and Carcinogenicity

Preparation for Phase I clinical trial of the best therapies bench marketed against MTX:
-Nanodevices with MTX and SSZ will offer improved tolerance and greater efficacy meaning that patients who do not do well on MTX will have cost-effective alternatives

Convocatoria de propuestas

H2020-NMP-2014-2015

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-NMP-PILOTS-2015

Régimen de financiación

RIA - Research and Innovation action

Coordinador

ASSOCIACAO UNIVERSIDADE EMPRESA PARA DESENVOLVIMENTO TECMINHO
Aportación neta de la UEn
€ 1 130 037,70
Dirección
CAMPUS DE AZUREM UNIVERSIDADE DO MINHO
4800 058 Guimaraes
Portugal

Ver en el mapa

Región
Continente Norte Ave
Tipo de actividad
Other
Enlaces
Coste total
€ 1 130 037,70

Participantes (10)